MDREU2017745欧盟医疗器械最新法规(中英对照版~).doc
《MDREU2017745欧盟医疗器械最新法规(中英对照版~).doc》由会员分享,可在线阅读,更多相关《MDREU2017745欧盟医疗器械最新法规(中英对照版~).doc(462页珍藏版)》请在得力文库 - 分享文档赚钱的网站上搜索。
1、#*欧盟官方欧盟官方公报公报中文版中文版立法立法L117第第 60 卷卷2017 年年 5 月月 5 日日内容内容I 立法法案立法法案法规法规欧洲议会和理事会于欧洲议会和理事会于 2017 年年 4 月月 5 日签发的关于医疗器械第日签发的关于医疗器械第 2017/745 号法号法规,修订了第规,修订了第 2001/83/EC 号指令,第号指令,第 178/2002 号(号(EU)法规和第)法规和第1223/2009 号(号(EU)法规,并废除了理事会第)法规,并废除了理事会第 90/385/EEC 号和第号和第93/42/EEC 号指令号指令(1)1欧洲议会和理事会于欧洲议会和理事会于 20
2、17 年年 4 月月 5 日签发的关于体外诊断医疗器械第日签发的关于体外诊断医疗器械第2017/746 号(号(EU)法规并废除了第)法规并废除了第 98/79/EC 号指令和理事会第号指令和理事会第2010/227/EU 号决议号决议176_(1)EEA 相关性文本。以浅色字体打印标题的法案均为涉及农业日常管理的法案,一般在有限期内有效。以浅色字体打印标题的法案均为涉及农业日常管理的法案,一般在有限期内有效。所有其他法案的标题均以粗体打印,并以星号开头。所有其他法案的标题均以粗体打印,并以星号开头。#*#*I(立法法案)(立法法案)法规法规欧洲议会和理事会于欧洲议会和理事会于 2017 年年
3、 4 月月 5 日签发的关于医疗器械第日签发的关于医疗器械第 2017/745 号法规,修订了号法规,修订了第第 2001/83/EC 号指令,第号指令,第 178/2002 号(号(EU)法规和第)法规和第 1223/2009 号(号(EU)法规,并废)法规,并废除了理事会第除了理事会第 90/385/EEC 号和第号和第 93/42/EEC 号指令号指令(EEA 相关性文本)相关性文本)欧洲议会和欧盟委员会,考虑到“欧盟运作条约” ,特别是其中第 114 条和第 168(4) (c)条规定,并考虑到欧盟委员会提案,于立法草案转交各国议会后,考虑到欧洲经济和社会委员会之意见(1) ,在咨询地
4、区委员之后,根据一般立法程序运作(2) ,鉴于:(1)理事会第 90/385/EEC 号指令(3)和理事会第 93/42/EEC 号指令(4)构成有关医疗器械(不包括体外诊断医疗器械)的欧盟监管框架。但需要对该指令进行大幅修订,以便建立稳健、透明、可预测和可持续的医疗器械监管框架,以确保高水平的安全和健康,同时为创新提供支持。Council Directive 90/385/EEC (3) and Council Directive 93/42/EEC (4) constitute the Union regulatory framework for medical devices, othe
5、r than in vitro diagnostic medical devices. However, a fundamental revision of those Directives is needed to establish a robust, transparent, predictable and sustainable regulatory framework for medical devices which ensures a high level of safety and health whilst supporting innovation.(2)本法规旨在确保区域
6、内医疗器械市场的平稳运作,在为患者和使用者提供高水平健康保护的基础上,同时考虑到活跃于本行业的中小型企业利益。同时,本法规为医疗器械的质量及安全性制定了较高标准,以满足器械产品常见安全问题的管控。这两个目标相辅相成、不可分割地联系在一起,并且在达成过程中没有主次顺序。关于欧盟运作条约(TFEU)第 114 条,本法规融合了上市销售以及将医疗器械及其附件投入欧盟市场的规则,这些规则可能受益于货物自由流通原则。针对 TFEU 第 168(4)(c)条,本法规通过确保临床研究的数据的可靠性和稳健性,来保障这些器械的质量及安全,并保障参与临床研究受试者的安全。This Regulation aims
7、to ensure the smooth functioning of the internal market as regards medical devices, taking as a base a high level of protection of health for patients and users, and taking into account the small- and medium-sized enterprises that are active in this sector. At the same time, this Regulation sets hig
8、h standards of quality and safety for medical devices in order to meet common safety concerns as regards such products. Both objectives are being pursued simultaneously and are inseparably linked whilst one not being secondary to the other. As regards Article 114 of the Treaty on the Functioning of
9、the European Union (TFEU), this Regulation harmonises the rules for the placing on the market and putting into service of medical devices and their accessories on the Union market thus allowing them to benefit from the principle of free movement of goods. As regards Article 168(4)(c) TFEU, this Regu
10、lation sets high standards of #*quality and safety for medical devices by ensuring, among other things, that data generated in clinical investigations are reliable and robust and that the safety of the subjects participating in a clinical investigation is protected._(1)2013 年 2 月 14 日意见(OJ C 133, 9.
11、5.2013, p. 52) 。(2)2014 年 4 月 2 日的欧洲议会立场(尚未在官方公告内公布)以及 2017 年 3 月 7 日首次审阅时理事会的立场(尚未在官方公告内公布) 。(3)1990 年 6 月 20 日签发的关于成员国有关可植入医疗器械法律的理事会第 90/38/EEC 号指令(OJ L 331, 7.12.1998, p.1) 。(4)1993 年 6 月 14 日签发的关于医疗器械的理事会第 93/42 EEC 号指令(OJ L 169,12.7.1993,p. 1) 。(3)本法规并不寻求协调有关医疗器械投入使用后,在市场上进一步供应之规则,例如二手销售。This
12、Regulation does not seek to harmonise rules relating to the further making available on the market of medical devices after they have already been put into service such as in the context of second-hand sales.(4) 应大大加强现有监管方法的关键要素,例如公告机构监管、符合性评估流程、临床研究和临床评价,警戒和市场监管,同时引入确保医疗器械透明度和可追溯性之规定,以改善健康和安全性。Key
13、elements of the existing regulatory approach, such as the supervision of notified bodies, conformity assessment procedures, clinical investigations and clinical evaluation, vigilance and market surveillance should be significantly reinforced, whilst provisions ensuring transparency and traceability
14、regarding medical devices should be introduced, to improve health and safety.(5) 如有可能,应当考虑到为医疗器械制定的国际指导准则,特别是全球协调工作队及其后续行动即“国际医疗器械监管机构论坛(IMDRF) ” ,以便推动世界范围内利于提高安全防护标准以及促进贸易之相关法规的全球化进程,特别是关于唯一器械标识、通用安全与性能要求、技术文件、分类标准、符合性评估流程和临床证据等方面的规定。To the extent possible, guidance developed for medical devices at
15、 international level, in particular in the context of the Global Harmonization Task Force (GHTF) and its follow-up initiative, the International Medical Devices Regulators Forum (IMDRF), should be taken into account to promote the global convergence of regulations which contributes to a high level o
16、f safety protection worldwide, and to facilitate trade, in particular in the provisions on Unique Device Identification, general safety and performance requirements, technical documentation, classification rules, conformity assessment procedures and clinical investigations.(6) 出于历史原因,第 90/385/EEC 号指
17、令所涵盖的有源植入式医疗器械以及第 93/42/EEC 号指令所涵盖的其他医疗器械通过另外两个单独的法律进行管控。为简化起见,经过若干次修订的两项指令均应替换为适用于除体外诊断医疗器械外所有医疗器械的单一立法法案。For historical reasons, active implantable medical devices, covered by Directive 90/385/EEC, and other medical devices, covered by Directive 93/42/EEC, were regulated in two separate legal inst
18、ruments. In the interest of simplification, both directives, which have been amended several times, should be replaced by a single legislative act applicable to all medical devices other than in vitro diagnostic medical devices.(7)本法规的适用范围应与其他相关产品的欧盟协调立法明确区分开, (如体外诊断医疗器械、医药产品、美容产品和食品) 。因此,应对欧洲议会和委员会
19、第 178/2002 号法规(1)进行修订,将医疗器械排除在其范围之外。The scope of application of this Regulation should be clearly delimited from other Union harmonisation legislation concerning products, such as in vitro diagnostic medical devices, medicinal products, cosmetics and food. Therefore, Regulation (EC) No 178/2002 of t
20、he European Parliament and of the Council (5) should be amended to exclude medical devices from its scope.(8)成员国有责任逐案例确认,各产品是否属于本法规范围。为确保所有成员国的相关判断力一致,特别是在灰区#*临界情况下,在咨询医疗器械协调小组(MDCG)后,应允许委员会主动或经成员国适时且有根据地请求,逐案决定某一具体产品、类别或产品组是否属于本法规适用范围。在审议涉及药品、人体组织和细胞、生物灭活产品或食品之临界案例所辖产品之监管状况时,委员会应确保欧洲药品管理局、欧洲化学品管理局和
21、欧洲食品安全局的适当咨询水平。It should be the responsibility of the Member States to decide on a case-by-case basis whether or not a product falls within the scope of this Regulation. In order to ensure consistent qualification decisions in that regard across all Member States, particularly with regard to borderl
22、ine cases, the Commission should be allowed to, on its own initiative or at the duly substantiated request of a Member State, having consulted the Medical Device Coordination Group (MDCG), decide on a case-by-case basis whether or not a specific product, category or group of products falls within th
23、e scope of this Regulation. When deliberating on the regulatory status of products in borderline cases involving medicinal products, human tissues and cells, biocidal products or food products, the Commission should ensure an appropriate level of consultation of the European Medicines Agency (EMA),
24、the European Chemicals Agency and the European Food Safety Authority, as relevant.(9)由于在某些情况下医疗器械和美容产品难以区分,因此欧盟议会和理事会第 1223/2009 号法规(2)中也应加入对某一产品法规状况的欧盟范围统一决议。Since in some cases it is difficult to distinguish between medical devices and cosmetic products, the possibility of taking a Union-wide deci
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- MDREU2017745 欧盟 医疗器械 最新 法规 中英对照
限制150内